Clinical Pathways
-
Read ArticleBending the Oncology Cost Curve in 2023 and Beyond
Our clinical leaders share three trends likely to impact oncology drug spend in the near future.
-
Watch VideoEmbracing Hope, Naming the Uncomfortable, and Empowering the Patient in Palliative Care
Our CMO Dr. Monica Soni, and American Cancer Society's Chief Patient Officer Dr. Arif Kamal discuss current challenges and the future of effective palliative care.
-
Read ArticleWhen Equality and Health Equity Diverge
Treating patients the same isn't always the path to improved outcomes, writes our associate chief medical officer.
-
Read Insight Brief
Targeting Overuse, Misuse and Underuse in Cardiovascular Care: Why Health Plans Need a Comprehensive Strategy
Learn key strategies for health plans to reduce three types of inappropriate use in cardiovascular care.
- Let's Go
-
Watch VideoPanel Discussion: Oncology Care Reimagined
Health plan clinical leaders joined us for an insightful discussion on the path toward high-value cancer care.
-
Listen to podcastEpisode 7: Underuse In Cardiology Is Under-Appreciated. How Do We Change That?
Learn why underuse is a major problem and how we might tackle it
-
Read External ArticleSpecialty Therapies Offering Incremental Benefit Shouldn’t Be Added to Clinical Pathways, Hertler Says
Evidence-Based Oncology interviews our CMO about mismatches between drug costs and efficacy.
-
Listen to podcast
Episode 6: Why Don't More Cardiology Patients Get Optimal Medication Therapy?
GDMT, or guideline-directed medical therapy, means taking the right medication at the optimal doses to treat cardiovascular problems. Yet these medications are chronically underused.
-
Listen to Podcast
Episode 5: Will COVID-19 Change What Is Considered Appropriate Use in Cardiology?
Every day, cardiologists make decisions about what is the most appropriate test, therapy, or procedure for their patients. But then COVID-19 came along. Have the rules of the game changed?
-
Read ArticleHealth Systems' Rare Rejection of Alzheimer's Drug Sparks Questions About FDA Approvals
Modern Healthcare spoke with NCH's Dr. Andrew Hertler about problems in the FDA's approval process.
- Learn More
-
Read ArticleSpecialty Pharmacies Grapple with Assessing Costs and Value of Oncology Therapies
Our CMO speaks with Formulary Watch about the challenges of high--cost drugs with marginal benefit.
-
Read ArticleHitting the Brakes on Fast-Tracked Drugs
The FDA's Aduhelm approval was highly controversial, but not as surprising for those who follow the oncology drug pipeline.
-
Watch VideoCMO Dr. Andrew Hertler Reacts to the FDA's Recent ODAC Meeting
New Century Health CMO, Dr. Andrew Hertler, shares his thoughts on the recent FDA meetings to review the merits of approved cancer drugs.
-
Read ArticleTraditional UM Programs Can't Move the Needle in Cardiology Care. Here's What Does.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
- Learn More
-
Read Article
Episode 2: Choice Paralysis
The therapeutic landscape in oncology is vast and everchanging, marked by a dramatic pace of innovation and new approvals. In this complicated specialty, how can payers and providers keep up?
-
Listen to Podcast
Introduction to Leading Causes: A Podcast by New Century Health
In this podcast series we explore the trends and forces behind the two leading causes of death in the United States: cancer and heart disease.
-
Read External ArticleCardiovascular Clinical Pathways Program at New Century Health
Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.
-
Read ArticleCan Clinical Pathways Help Combat Health Care Disparities?
A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.
-
Read ArticlePathways, Portals and Persuasion: Reining in an Overused Cancer Agent
NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.
-
Read ArticleHow Real-World Evidence Can Transform High-Value Oncology Pathways
Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.
-
Loading More...
